| 常用名 | 杜拉鲁肽 | CAS号 | 923950-08-7 |
|---|---|---|---|
| 价格 | $242.63/10mg $4872.6/1g | 纯度 | 99.71% |
| 备货期 | 3天 | 库存 | 现货 |
| 产品网页 | http://www.zhaokebio.com | ||
| 产品详情(用途,包装等)
Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist consisting of a GLP-1 analog covalently linked to a modified human immunoglobulin G4 (IgG4) Fc fragment. It is approved for the treatment of type 2 diabetes mellitus (T2DM) as a once-weekly subcutaneous injection, offering sustained glycemic control with reduced dosing frequency compared to daily GLP-1 agonists. Product Highlights: Once-Weekly Dosing: Fusion to human IgG4-Fc extends half-life to ~5 days via FcRn recycling, enabling convenient once-weekly subcutaneous administration. Superior patient adherence compared to daily GLP-1 injections; strong competitive positioning in the T2DM market. Cardiovascular Benefits: Demonstrated reduction in major adverse cardiovascular events (MACE) in the REWIND trial - 12% relative risk reduction versus placebo. Cardioprotective profile supports premium pricing and broad formulary inclusion in diabetes management protocols. Fusion Protein Design: Novel GLP-1-IgG4 Fc fusion construct provides exceptional metabolic stability and reduced immunogenicity compared to pegylated alternatives. Proven biologic platform technology with established manufacturing processes and regulatory pathway. Weight Loss Efficacy: Clinically meaningful weight reduction (average 3-4.5 kg) alongside glycemic control, addressing dual metabolic goals. Growing demand from the intersection of diabetes and obesity therapeutics with expanding label potential. |